Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?
Recorded April 24, 2020.
Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the ways in which coronavirus reshaped Italian hospitals, mistakes made, and lessons learned. Filmed April 15, 2020.
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?
Recorded April 24, 2020.
Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.
